The seasonal duration of daylight influences the number of opioid receptors in the brain. The findings shed new light on a potential mechanism behind seasonal affective disorder.
A new automated method can identify and track the development of tau deposits in the brain. The method could lead to an earlier diagnosis of Alzheimer's disease.
Parkinson's disease can be divided into two variants that start in different places in the body. For some, the neurodegenerative disease starts in the intestines and spreads to the brain. In others, the disease begins in the brain and spreads to the intestines and other organs.
Blood samples taken from people enrolled in an Alzheimer's research study revealed higher levels of phosphorylated tau 217 that correlated with the presence of amyloid plaques. People with amyloid in their brains had up to three times more of the tau protein in their blood than those who had no evidence of amyloid accumulation. The higher levels of the protein were evident even in people with no signs of cognitive decline.
PET neuroimaging reveals super-agers and those whose cognitive skills are above the norm for an advanced age have an increased resistance to tau and amyloid proteins.
Genetic analysis of almost 4,300 samples reveals a link between the appearance of amyloid deposits, APOE, and a novel gene called RBFOX1. Lower levels of RBFOX1 in the brain appear to be associated with increased amyloid and global cognitive decline over a person's lifetime.
Study reveals how the brain's opioid system is linked to mood changes associated with depression and anxiety. Neuroimaging revealed, in those with depression, there is a decreased number of opioid receptors in specific areas of the brain.
Computational simulations reveal the integration of both neuronal and neurotransmitter systems at a whole-brain level is vital to fully understand the effects of psilocybin on brain activity.
Neuroimaging technology has limited applicability when assessing a defendant's sanity, a new study reports.